An interventional study of Diagnosis of MCI versus No MCI (SCI or healthy patient) and Diagnosis of MCI versus No MCI (SCI or healthy patient) in Mild Cognitive Impairment (MCI), sponsored by Assistance Publique Hopitaux De Marseille. Completed at 1 site in France. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2026-10-26.
Sponsored by Assistance Publique Hopitaux De Marseille · Not applicable, Interventional, and Diagnostic
Le Tirant L, Likhanov M, Mazerolle M, Morand A, Eustache F, Huguet P; AGING Consortium; Regner I. Self-Perceptions of Aging in Older Adults: A Network Analysis…PubMed 41750205 ↗; 1 more
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 189 studies in Cognitive Dysfunction with a site in France — 52 open to participants now, 60 under way, 6 of them phase 3. Cognitive Dysfunction · France.
Among the 189 studies in Cognitive Dysfunction with a site in France, this one is the 57th largest by enrollment of the 139 interventional ones that give a count, is one of 5 that started in 2018, is one of 104 with no phase, and was the 71st registered.
3,885 studies on the registry are indexed under Cognitive Dysfunction; 1,123 are open to participants now.
Browse Cognitive Dysfunction studies →52 of the 189 studies in Cognitive Dysfunction with a site in France are open now. Recruiting first, the newest first:
University Hospital, Angers · Sites in France
Ages 60+
Nadine ATTAL · Sites in France
Ages 35–65 · Women only
Aelis Farma · Sites in France, Italy, Spain
Ages 16–32
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 7–20
LNA SANTE · Sites in France
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 751 Cognitive Dysfunction studies recruiting now, 361 (48%) set no upper age limit and 144 (19%) stop at 75 or younger; 46 take children under 18; 260 take healthy volunteers.
This study: 50 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
189 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 15 · Phase 3 17 · Phase 4 1
First in 2003; this study’s year is marked. 5 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 130 is above the median of 64 across 2,804 interventional studies indexed under Cognitive Dysfunction.
Median enrollment 88 across the 139 interventional studies, 160 across the 50 observational. Of the 110 that completed or were terminated, 12 (11%) have results posted.
This tab as a report to print or save as PDF → With an account.
35 of 189 have an industry lead sponsor. The 10 most frequent:
Assistance Publique Hopitaux De Marseille is the lead sponsor of 702 studies on the registry; 139 are open to participants now.
Assistance Publique Hopitaux De Marseille has 2 studies filed under Cognitive Dysfunction — fewer than ten, so there is no comparison to draw.
18 of the studies in Cognitive Dysfunction with a site in France that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03887455Phase 3Eisai Inc.A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease | 2026-12-31 |
| NCT07237009KompanionCare SASEffects of Personalized Digital Reminiscence Therapy on Patients With Neurocognitive Disorders | 2026-12 |
| NCT07083089Cilcare SASEarly Stage of Alzheimer's and Parkinson's Diseases, HearIng Relevance (SAPHIR) | 2026-12 |
| NCT07877376Nadine ATTALImpact of Cognitive Impairment on Chronic Pain in Breast Cancer | 2027-01 |
| NCT05790707Poitiers University HospitalEfFect of Ablation of Persistent AtriaL Fibrillation on COgNitive Function in Individuals With Mild Cognitive Impairment | 2027-01 |
Add all 18 to your calendar (.ics) → With an account.
Among the 189 studies in Cognitive Dysfunction with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Because of the lengthening of life expectancy, more and more people are concerned with the effects of aging on their mental faculties (e.g., memory decline) and with the possibility of getting Alzheimer's Disease (AD) or other forms of dementia. This increasing awareness of AD has already resulted in a growing demand for neuropsychological testing. AD's research also emphasizes the need for early screening to improve the prediction of the disease progression and the efficacy of any future therapy. Such a drive to screen for pre-dementia raises the challenging issue of frontline identification of individuals in the preclinical or early clinical stages of AD. Mild Cognitive Impairment (MCI) is typically considered to be the prodromal state of AD, and is therefore at the core of the drive for early screening. Moreover, Pre-MCI so called SCI (Subjective Cognitive Impairment) can precede AD for 15 years. However, many individuals diagnosed with MCI do not convert to AD, some remaining stable and others even reversing back to normal (with rates of reversion to normal varying from 4.5% to as high as 53%). This over-diagnosis bias, which has been largely overlooked, is at the core of the present project at the interface of human and life sciences. Here, we argue that an important source of overdiagnosis in the prodromal state of AD comes from negative aging stereotypes (e.g., the culturally shared beliefs that aging inescapably causes severe cognitive decline and diseases such as AD) that permeate neuropsychological screening. There is ample evidence in the laboratory that such stereotypes contribute to the differences observed in the healthy population between younger and older adults in explicit memory tasks. Additionally, three pilot (lab) studies specifically conducted for the present ANR project showed that the threat of being judged stereotypically undermines the controlled use of memory of healthy older adults and simultaneously intensifies their automatic response tendencies, resulting in impaired memory performance. The present proposal goes several steps further by examining for the first time whether aging stereotypes are powerful enough to implicitly permeate the clinical neuropsychological testing and thus inflate memory deficits in older adults judged "at risk" (based on either epidemiological criteria or memory complaints), resulting in false-positive detection of SCI and MCI. This provocative hypothesis will be tested while 1) using biomarkers of neurodegeneration to distinguish false-positives from true MCI, and 2) using biomarkers of stress to examine whether and how aging stereotypes can lead to acute physiological stress during neuropsychological testing. This innovative project has the potential to offer new recommendations to improve the diagnosis accuracy of prodromal state of AD, with positive consequences for older people's wellbeing.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Diagnostic Test: Diagnosis of MCI versus No MCI (SCI or healthy patient)
Diagnostic Test: Diagnosis of MCI versus No MCI (SCI or healthy patient)
Neuropsychological tests
Neuroimaging biomarkers of neurodegeneration
Neuropsychological tests
Neuropsychological battery used for the diagnosis of Mild Cognitive Impairment (MCI, amnestic single or multiple domain)
Time frame: 48 months
Neuroimaging biomarkers of neurodegeneration
Structural MRI (Hippocamp) and Florbetapir© PET (β-amyloid deposition)
Time frame: 48 months
Physiological stress
cortisol, dehydroepiandrosterone (DHEA) and its sulfated stable form (DHEAS) from the HPA axis, and Immunoglobulin A (IgA).
Time frame: 48 months
Self-report questionnaires
Vulnerability factors for stereotyping threat effects are assessed
Time frame: 48 months
Heart rate variability (thin elasticized heart rate transmitter belt),
Physiological stress
Time frame: 48 months
Skin conductance (wristwatch)
Physiological stress
Time frame: 48 months
Salivary biomarkers
cortisol, dehydroepiandrosterone (DHEA) and its sulfated stable form (DHEAS) from the HPA axis, and Immunoglobulin A (IgA).
Time frame: 48 months
Plan to share: No
Ran from Jul 2018 to primary completion in Aug 2023, 61 months.
Of 1,453 non-industry interventional studies with no phase under Cognitive Dysfunction, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 51. This study's 61 months is above that.
Counting every sponsor, half of 1,522 studies reached it within 27 months; a quarter within 12 and three quarters within 50.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 21, 2026: primary completion Jul 2023 → Aug 2023 and completion Jul 2023 → Aug 2023.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
Le Tirant L, Likhanov M, Mazerolle M, Morand A, Eustache F, Huguet P; AGING Consortium; Regner I. Self-Perceptions of Aging in Older Adults: A Network Analysis…PubMed 41750205 ↗; 1 more
Le Tirant L, Likhanov M, Mazerolle M, Morand A, Eustache F, Huguet P; AGING Consortium; Regner I. Self-Perceptions of Aging in Older Adults: A Network Analysis…PubMed 41750205 ↗; 1 more
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Assistance Publique Hopitaux De Marseille →